- Consumables
- Tissue Processing Systems
- Imaging Devices
Cancer Diagnostics Market size was valued at USD 122.4 billion in 2022 and is anticipated to grow at a CAGR of 7.8 % over 2023-2029. The cancer diagnostics market is a rapidly growing and vital segment of the healthcare sector focused on cancer detection and diagnosis. Cancer diagnostics, which include a variety of diagnostic tests, imaging procedures, and laboratory analyses, play an important role in cancer detection, allowing healthcare providers to provide timely and effective treatment options, resulting in better patient outcomes and survival rates. The increased cancer prevalence is majorly driving the cancer diagnostics market. Cancer is one of the main causes of mortality globally, with millions of new cases diagnosed each year. According to the American Cancer Society 2022, approximately 1.9 million new cancer cases were diagnosed across the USA and more than 6 lakh deaths occurred with the disease. Moreover, advancements in early detection and diagnosis technologies have revolutionized cancer diagnostics, fueling the cancer diagnostics market's development. Furthermore, advancements in biomarker discovery and rising demand for liquid biopsy create significant opportunities for the growth and development of the cancer diagnostics market. On top of that some of the recent trends such as the incorporation of artificial intelligence (AI) and machine learning with diagnostic tools and point-of-care (POC) cancer diagnostics devices are shaping the cancer diagnostics market. However, the high costs of diagnostic tests, as well as stringent regulatory approval processes, act as restraints to the growth of the cancer diagnostics market. Major market players are focusing on the development of innovative solutions to provide better patient outcomes, early detection, and improved treatment strategies in the fight against cancer. For instance, in December 2022, Digistain launched a new revolutionary AI breast cancer diagnostic tool.
The Cancer Diagnostics Market Key Developments:
- In July 2023, CORE Diagnostics announced its collaboration with PredOmix Technologies to launch OncoVeryx-F, a multi-cancer detection test specifically designed for high-risk and asymptomatic women. This technology offers screening solutions for four cancers, including breast, endometrial, cervical, and ovarian cancer
- In Jun-2022, Roche launched new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care.
Cancer Diagnostics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7.80%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Cancer Diagnostics Market Dynamics
The rising demand for Personalized Medicine is majorly driving the expansion of the cancer diagnostics market. Cancer diagnostics are critical components of personalized medicine techniques. Identifying precise genetic and molecular abnormalities in tumors helps doctors to personalize treatment approaches to each patient's cancer's unique features. Furthermore, rising public awareness of cancer and the need for early diagnosis has resulted in increasing screening rates and increased demand for cancer diagnostic tests. In addition, governments and healthcare organizations throughout the world are expanding their investments in cancer research and diagnostic programs. This financial assistance promotes the development and implementation of innovative cancer diagnostic technology.
North-America Got Significant Share of
Cancer Diagnostics Market Region Analysis
North America holds a significant share in the Cancer Diagnostics Market due to its sophisticated healthcare infrastructure, high healthcare expenditure, and strong research and development activities. The presence of prominent market participants in the United States, as well as a focus on early cancer diagnosis, fuels the growth of the cancer diagnostics market in this region. Europe is another key market for cancer diagnostics, owing to a huge patient pool, greater cancer awareness, and supportive government initiatives. Countries with well-established healthcare systems and significant investments in cancer research, such as Germany, the United Kingdom, and France, are essential contributors to the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Cancer Diagnostics Market Segmentation
By Product Type
By Technology
- In-Vitro Diagnostics Techniques
- Molecular Diagnostics Techniques
- Imaging Technique
- Biopsy Techniques
By Application
- Breast Cancer
- Lung Cancer
- Kidney Cancer
- Liver Cancer
- Skin Cancer
- Prostate Cancer
- Others
By End User
- Hospitals and Diagnostic Centers
- Cancer Clinics
- Academic and Research Institutes
- Others
Frequently Asked Questions
The cancer diagnostics market was valued at USD 122.4 Million in 2022 and is expected to grow at 7.8 % CAGR over the forecast period 2023 – 2029.
Rising cancer prevalence, technological advancements in diagnostic tools, and rising demand for personalized medicine are some of the factors that create potential opportunities for the growth of the cancer diagnostics market.
The integration of AI and ML to the diagnostic tools, point-of-care cancer diagnostic tools are some of the major trends in the cancer diagnostics market.
Abbott, DiagnoCure Inc., Thermo Fisher Scientific, Illumina, Inc., QIAGEN, Volpara Solutions Limited, Quest Diagnostics Incorporated., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Hologic, Inc., Astellas Pharma Inc., Merck KGaA, GE healthcare, CORE Diagnostics, Siemens Healthcare GmbH, Bristol-Myers Squibb Company, NeoGenomics Laboratories, Inc., Philips Healthcare, Digistain, BD, bioMérieux SA, GSK plc., Novartis AG, Lilly, Pfizer, Inc. are a few companies operating in cancer diagnostics market.
| 1. Executive Summary |
| 2. Global Cancer Diagnostics Market Introduction |
| 2.1. Global Cancer Diagnostics Market - Taxonomy |
| 2.2. Global Cancer Diagnostics Market - Definitions |
| 2.2.1. Technology |
| 2.2.2. Application |
| 2.2.3. Product |
| 2.2.4. End User |
| 2.2.5. Region |
| 3. Global Cancer Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 3.8. USP |
| 3.9. Macro Trends |
| 3.10. Epidemiology |
| 3.11. PEST and PORTER Analysis |
| 4. Global Cancer Diagnostics Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cancer Diagnostics Market By Technology, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. In-Vitro Diagnostics Techniques |
| 5.1.1. Immunohistochemistry (IHC) |
| 5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Immunoassays |
| 5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Flow Cytometry |
| 5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.1.4. Others |
| 5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.4.3. Market Opportunity Analysis |
| 5.2. Molecular Diagnostics Techniques |
| 5.2.1. PCR and Sanger dideoxy sequencing |
| 5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. MLPA |
| 5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Next-generation Sequencing (NGS) |
| 5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.2.4. BEAMing |
| 5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.4.3. Market Opportunity Analysis |
| 5.2.5. Others |
| 5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.5.3. Market Opportunity Analysis |
| 5.3. Imaging technique |
| 5.3.1. Magnetic Resonance Imaging (MRI) |
| 5.3.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Computed Tomography (CT) |
| 5.3.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 5.3.3. Positron Emission Tomography (PET) |
| 5.3.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 5.3.3.3. Market Opportunity Analysis |
| 5.3.4. Mammography |
| 5.3.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 5.3.4.3. Market Opportunity Analysis |
| 5.3.5. Ultrasound |
| 5.3.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 5.3.5.3. Market Opportunity Analysis |
| 5.4. Biopsy Techniques |
| 5.4.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Cancer Diagnostics Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Breast Cancer |
| 6.1.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lung Cancer |
| 6.2.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Kidney Cancer |
| 6.3.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Liver Cancer |
| 6.4.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Skin Cancer |
| 6.5.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Prostate Canacer |
| 6.6.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018-2022 and Forecast,.2023-2029, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. Global Cancer Diagnostics Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Consumables |
| 7.1.1. Antibodies |
| 7.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.1.3. Market Opportunity Analysis |
| 7.1.2. Kits & Reagents |
| 7.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.2.3. Market Opportunity Analysis |
| 7.1.3. Probes |
| 7.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3.3. Market Opportunity Analysis |
| 7.1.4. Other Consumables |
| 7.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.4.3. Market Opportunity Analysis |
| 7.2. Instruments |
| 7.2.1. Tissue Processing Systems |
| 7.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.1.3. Market Opportunity Analysis |
| 7.2.2. Cell Processors |
| 7.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.2.3. Market Opportunity Analysis |
| 7.2.3. PCR Instruments |
| 7.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3.3. Market Opportunity Analysis |
| 7.2.4. NGS Instruments |
| 7.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.4.3. Market Opportunity Analysis |
| 7.2.5. Others |
| 7.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.5.3. Market Opportunity Analysis |
| 7.3. Imaging Devices |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Cancer Diagnostics Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Hospitals and Diagnostic Centers |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Cancer Clinics |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Acadmic and Research institutes |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Others |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9.Global Cancer Diagnostics Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa (MEA) |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Cancer Diagnostics Market - Opportunity Analysis Index, By Application, Technology, Product, End User, , , , and Region, 2023-2029 |
| 10. North America Cancer Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Technology Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. In-Vitro Diagnostics Techniques |
| 10.1.1.1. Immunohistochemistry (IHC) |
| 10.1.1.2. Immunoassays |
| 10.1.1.3. Flow Cytometry |
| 10.1.1.4. Others |
| 10.1.2. Molecular Diagnostics Techniques |
| 10.1.2.1. PCR and Sanger dideoxy sequencing |
| 10.1.2.2. MLPA |
| 10.1.2.3. Next-generation Sequencing (NGS) |
| 10.1.2.4. BEAMing |
| 10.1.2.5. Others |
| 10.1.3. Imaging technique |
| 10.1.3.1. Magnetic Resonance Imaging (MRI) |
| 10.1.3.2. Computed Tomography (CT) |
| 10.1.3.3. Positron Emission Tomography (PET) |
| 10.1.3.4. Mammography |
| 10.1.3.5. Ultrasound |
| 10.1.4. Biopsy Techniques |
| 10.2. Application Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Breast Cancer |
| 10.2.2. Lung Cancer |
| 10.2.3. Kidney Cancer |
| 10.2.4. Liver Cancer |
| 10.2.5. Skin Cancer |
| 10.2.6. Prostate Canacer |
| 10.3. Product Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Consumables |
| 10.3.1.1. Antibodies |
| 10.3.1.2. Kits & Reagents |
| 10.3.1.3. Probes |
| 10.3.1.4. Other Consumables |
| 10.3.2. Instruments |
| 10.3.2.1. Tissue Processing Systems |
| 10.3.2.2. Cell Processors |
| 10.3.2.3. PCR Instruments |
| 10.3.2.4. NGS Instruments |
| 10.3.2.5. Others |
| 10.3.3. Imaging Devices |
| 10.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1. Hospitals and Diagnostic Centers |
| 10.4.2. Cancer Clinics |
| 10.4.3. Acadmic and Research institutes |
| 10.4.4. Others |
| 10.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1. United States of America (USA) |
| 10.5.2. Canada |
| 11. Europe Cancer Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Technology Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. In-Vitro Diagnostics Techniques |
| 11.1.1.1. Immunohistochemistry (IHC) |
| 11.1.1.2. Immunoassays |
| 11.1.1.3. Flow Cytometry |
| 11.1.1.4. Others |
| 11.1.2. Molecular Diagnostics Techniques |
| 11.1.2.1. PCR and Sanger dideoxy sequencing |
| 11.1.2.2. MLPA |
| 11.1.2.3. Next-generation Sequencing (NGS) |
| 11.1.2.4. BEAMing |
| 11.1.2.5. Others |
| 11.1.3. Imaging technique |
| 11.1.3.1. Magnetic Resonance Imaging (MRI) |
| 11.1.3.2. Computed Tomography (CT) |
| 11.1.3.3. Positron Emission Tomography (PET) |
| 11.1.3.4. Mammography |
| 11.1.3.5. Ultrasound |
| 11.1.4. Biopsy Techniques |
| 11.2. Application Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Breast Cancer |
| 11.2.2. Lung Cancer |
| 11.2.3. Kidney Cancer |
| 11.2.4. Liver Cancer |
| 11.2.5. Skin Cancer |
| 11.2.6. Prostate Canacer |
| 11.3. Product Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Consumables |
| 11.3.1.1. Antibodies |
| 11.3.1.2. Kits & Reagents |
| 11.3.1.3. Probes |
| 11.3.1.4. Other Consumables |
| 11.3.2. Instruments |
| 11.3.2.1. Tissue Processing Systems |
| 11.3.2.2. Cell Processors |
| 11.3.2.3. PCR Instruments |
| 11.3.2.4. NGS Instruments |
| 11.3.2.5. Others |
| 11.3.3. Imaging Devices |
| 11.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1. Hospitals and Diagnostic Centers |
| 11.4.2. Cancer Clinics |
| 11.4.3. Acadmic and Research institutes |
| 11.4.4. Others |
| 11.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. France |
| 11.5.3. Italy |
| 11.5.4. United Kingdom (UK) |
| 11.5.5. Spain |
| 11.5.6. Rest of EU |
| 12. Asia Pacific (APAC) Cancer Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Technology Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. In-Vitro Diagnostics Techniques |
| 12.1.1.1. Immunohistochemistry (IHC) |
| 12.1.1.2. Immunoassays |
| 12.1.1.3. Flow Cytometry |
| 12.1.1.4. Others |
| 12.1.2. Molecular Diagnostics Techniques |
| 12.1.2.1. PCR and Sanger dideoxy sequencing |
| 12.1.2.2. MLPA |
| 12.1.2.3. Next-generation Sequencing (NGS) |
| 12.1.2.4. BEAMing |
| 12.1.2.5. Others |
| 12.1.3. Imaging technique |
| 12.1.3.1. Magnetic Resonance Imaging (MRI) |
| 12.1.3.2. Computed Tomography (CT) |
| 12.1.3.3. Positron Emission Tomography (PET) |
| 12.1.3.4. Mammography |
| 12.1.3.5. Ultrasound |
| 12.1.4. Biopsy Techniques |
| 12.2. Application Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Breast Cancer |
| 12.2.2. Lung Cancer |
| 12.2.3. Kidney Cancer |
| 12.2.4. Liver Cancer |
| 12.2.5. Skin Cancer |
| 12.2.6. Prostate Canacer |
| 12.3. Product Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Consumables |
| 12.3.1.1. Antibodies |
| 12.3.1.2. Kits & Reagents |
| 12.3.1.3. Probes |
| 12.3.1.4. Other Consumables |
| 12.3.2. Instruments |
| 12.3.2.1. Tissue Processing Systems |
| 12.3.2.2. Cell Processors |
| 12.3.2.3. PCR Instruments |
| 12.3.2.4. NGS Instruments |
| 12.3.2.5. Others |
| 12.3.3. Imaging Devices |
| 12.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1. Hospitals and Diagnostic Centers |
| 12.4.2. Cancer Clinics |
| 12.4.3. Acadmic and Research institutes |
| 12.4.4. Others |
| 12.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1. China |
| 12.5.2. India |
| 12.5.3. Australia and New Zealand (ANZ) |
| 12.5.4. Japan |
| 12.5.5. Rest of APAC |
| 13. Latin America Cancer Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Technology Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. In-Vitro Diagnostics Techniques |
| 13.1.1.1. Immunohistochemistry (IHC) |
| 13.1.1.2. Immunoassays |
| 13.1.1.3. Flow Cytometry |
| 13.1.1.4. Others |
| 13.1.2. Molecular Diagnostics Techniques |
| 13.1.2.1. PCR and Sanger dideoxy sequencing |
| 13.1.2.2. MLPA |
| 13.1.2.3. Next-generation Sequencing (NGS) |
| 13.1.2.4. BEAMing |
| 13.1.2.5. Others |
| 13.1.3. Imaging technique |
| 13.1.3.1. Magnetic Resonance Imaging (MRI) |
| 13.1.3.2. Computed Tomography (CT) |
| 13.1.3.3. Positron Emission Tomography (PET) |
| 13.1.3.4. Mammography |
| 13.1.3.5. Ultrasound |
| 13.1.4. Biopsy Techniques |
| 13.2. Application Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Breast Cancer |
| 13.2.2. Lung Cancer |
| 13.2.3. Kidney Cancer |
| 13.2.4. Liver Cancer |
| 13.2.5. Skin Cancer |
| 13.2.6. Prostate Canacer |
| 13.3. Product Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Consumables |
| 13.3.1.1. Antibodies |
| 13.3.1.2. Kits & Reagents |
| 13.3.1.3. Probes |
| 13.3.1.4. Other Consumables |
| 13.3.2. Instruments |
| 13.3.2.1. Tissue Processing Systems |
| 13.3.2.2. Cell Processors |
| 13.3.2.3. PCR Instruments |
| 13.3.2.4. NGS Instruments |
| 13.3.2.5. Others |
| 13.3.3. Imaging Devices |
| 13.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1. Hospitals and Diagnostic Centers |
| 13.4.2. Cancer Clinics |
| 13.4.3. Acadmic and Research institutes |
| 13.4.4. Others |
| 13.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Rest of LA |
| 14. Middle East and Africa (MEA) Cancer Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Technology Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. In-Vitro Diagnostics Techniques |
| 14.1.1.1. Immunohistochemistry (IHC) |
| 14.1.1.2. Immunoassays |
| 14.1.1.3. Flow Cytometry |
| 14.1.1.4. Others |
| 14.1.2. Molecular Diagnostics Techniques |
| 14.1.2.1. PCR and Sanger dideoxy sequencing |
| 14.1.2.2. MLPA |
| 14.1.2.3. Next-generation Sequencing (NGS) |
| 14.1.2.4. BEAMing |
| 14.1.2.5. Others |
| 14.1.3. Imaging technique |
| 14.1.3.1. Magnetic Resonance Imaging (MRI) |
| 14.1.3.2. Computed Tomography (CT) |
| 14.1.3.3. Positron Emission Tomography (PET) |
| 14.1.3.4. Mammography |
| 14.1.3.5. Ultrasound |
| 14.1.4. Biopsy Techniques |
| 14.2. Application Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Breast Cancer |
| 14.2.2. Lung Cancer |
| 14.2.3. Kidney Cancer |
| 14.2.4. Liver Cancer |
| 14.2.5. Skin Cancer |
| 14.2.6. Prostate Canacer |
| 14.3. Product Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1. Consumables |
| 14.3.1.1. Antibodies |
| 14.3.1.2. Kits & Reagents |
| 14.3.1.3. Probes |
| 14.3.1.4. Other Consumables |
| 14.3.2. Instruments |
| 14.3.2.1. Tissue Processing Systems |
| 14.3.2.2. Cell Processors |
| 14.3.2.3. PCR Instruments |
| 14.3.2.4. NGS Instruments |
| 14.3.2.5. Others |
| 14.3.3. Imaging Devices |
| 14.4. End User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1. Hospitals and Diagnostic Centers |
| 14.4.2. Cancer Clinics |
| 14.4.3. Acadmic and Research institutes |
| 14.4.4. Others |
| 14.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1. GCC Countries |
| 14.5.2. South Africa |
| 14.5.3. Rest of MEA |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. GE Healthcare |
| 15.2.2. Hologic Inc. |
| 15.2.3. F. Hoffmann-La Roche Ltd |
| 15.2.4. bioMérieux SA |
| 15.2.5. Siemens Healthcare GmbH |
| 15.2.6. Thermo Fisher Scientific, Inc. |
| 15.2.7. Hologic, Inc. |
| 15.2.8. Agilent Technologies, Inc. |
| 15.2.9. Illumina, Inc. |
| 15.2.10. Becton, Dickinson and Company |
| 15.2.11. QIAGEN N.V. |
| 15.2.12. Abbott Laboratories, Inc. |
| 15.2.13. Philips Healthcare |
| 15.2.14. NeoGenomics Laboratories, Inc. |
| 15.2.15. Volpara Solutions Limited |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Abbott Laboratories
- Siemens Healthineers
- Becton, Dickinson and Company
- Illumina, Inc.
- Bio-Rad Laboratories
- Roche Diagnostics
- Qiagen N.V.
- ThermoFisher Scientific, Inc.
- Quest Diagnostics
- bioMérieux SA
- MDNA Life Sciences, Inc.